Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

OncoSynergy

OncoSynergy
2011 FOUNDED
PRIVATE STATUS
Series A1 LATEST DEAL TYPE
$1.15M LATEST DEAL AMOUNT
5 INVESTORS
Description

Developer of oncology therapeutics designed to radically improve outcomes for patients with unmet needs in oncology. The company's therapeutics include a new class of oncology called Resistance Mechanism Inhibitors (RMIs), that feature multiple simultaneous mechanisms of action and synergy in combination with other treatments, including immunotherapies in a preclinical model, enabling oncologists to treat haematological cancers easily.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Greenwich, CT
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore OncoSynergy’s full profile, request a free trial.

OncoSynergy Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Early Stage VC (Series A1) 02-Aug-2019 $1.15M 000.00 000.00 Completed Generating Revenue
5. Seed Round 14-May-2018 0000 000.00 0000 Completed Generating Revenue
4. Accelerator/Incubator 19-May-2017 000.00 Completed Generating Revenue
3. Accelerator/Incubator 000.00 Completed Generating Revenue
2. Merger/Acquisition 05-Apr-2016 Cancelled Generating Revenue
1. Seed Round 28-Jun-2015 $10.2M $10.2M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

OncoSynergy Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A1 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

OncoSynergy Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kesios Venture Capital-Backed Cambridge, United Kingdom 00 0000 000000 - 000 0000
00000000 Venture Capital-Backed Tübingen, Germany 000 00000 00000000000 00000
000 0000000000000 Venture Capital-Backed Chester, United Kingdom 00 000.00 00000000000 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

OncoSynergy Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
Korea Information & Communications Company Corporation Minority 000 0000 000000 0
NLabs Family Office Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
California Institute for Quantitative Biosciences Accelerator/Incubator Minority 000 0000 000000 0

OncoSynergy Executive Team (3)

Name Title Board
Seat
Contact
Info
Shawn Carbonell Ph.D Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Board Member
Catherine Park MD Co-Founder
Anne-Marie Carbonell Co-Founder, Chief Medical Officer & Board Member

OncoSynergy Board Members (5)

Name Representing Role Since Contact
Info
Allen Salmasi Ph.D Self Chairman 000 0000
Amanda Hayward Ph.D Connecticut Innovations Board Member 000 0000
Anne-Marie Carbonell OncoSynergy Co-Founder, Chief Medical Officer & Board Member 000 0000
Hen-Suh Park Ph.D OncoSynergy Board Member 000 0000
Robert Dunkle OncoSynergy Board Member 000 0000